A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Trial Profile

A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Talimogene laherparepvec (Primary)
  • Indications Breast cancer; Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 05 Oct 2017 Planned End Date changed from 20 Dec 2020 to 25 Apr 2021.
    • 05 Oct 2017 Planned primary completion date changed from 11 Feb 2019 to 24 Jun 2019.
    • 05 Oct 2017 Planned initiation date changed from 29 Sep 2017 to 2 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top